MediWound Announces Peer-Reviewed Publication Of New Prospective Clinical Data Showing NexoBrid Substantially Reduces Embedded Particles Associated With Traumatic Tattoos Following Abrasion And Blast Injuries

MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

Prospective clinical data show NexoBrid® removes embedded particles in friction and blast wounds, reducing pigmented wound surface by >90%

Traumatic tattoos form when dirt, metal, or explosive residue becomes permanently embedded in the skin; findings support further evaluation in acute trauma settings

YAVNE, Israel, December 10, 2025 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the peer-reviewed publication of new prospective clinical data showing that NexoBrid® substantially reduces embedded particles associated with traumatic tattoos following abrasion and blast injuries.

Traumatic tattoos occur when high-velocity accidents or blasts drive materials such as asphalt, dirt, glass, or metallic particles (shrapnel) into the skin, often leaving not only permanent dark discoloration but also causing aesthetic deformities, functional impairment, and increased risk of inflammation or infection. Current standard of care relies on aggressive non-selective mechanical scrubbing, which may leave embedded particles behind and may risk damage to viable tissue.